^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Waldenstrom Macroglobulinemia |
| Drug: | Arzerra (ofatumumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
...the NCCN Panel has included newer agents as therapy options for previously treated disease, such as everolimus, ibrutinib and ofatumumab.
